On March 16, 2025, Zydus Lifesciences received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg, which are used to treat irritable bowel syndrome with diarrhoea, with an annual market value of USD 243.7 million in the US.